Turkish Journal of Gastroenterology最新文献

{"title":"Epigenetics and Expression of the Wnt Signaling Pathway in Ulcerative Colitis.","authors":"Zuhal Altintas, Mehmet Emin Erdal, Engin Altintas","doi":"10.5152/tjg.2025.24619","DOIUrl":"https://doi.org/10.5152/tjg.2025.24619","url":null,"abstract":"<p><strong>Background/aims: </strong>Secreted frizzled-related proteins (SFRPs) are antagonists that bind Wnt and inhibit signaling through this pathway. Secreted frizzled-related proteins are silenced by promoter methylation and cause hyperactivation of the Wnt pathway. In this study, the aim was to evaluate the relationship between methylation and expression of genes involved in the Wnt signaling pathway and the risk of cancer development in inflammatory bowel disease.</p><p><strong>Materials and methods: </strong>The patient group consisted of 20 individuals who were diagnosed with left-side ulcerative colitis and underwent surveillance colonoscopy; the control group consisted of 15 individuals without symptoms and endoscopic pathology who were screened for colorectal cancer. Tissue samples were obtained from inflamed and non-inflamed areas of the colon. Methylation and gene expression profiles of the Wnt pathway genes APC1A, APC2, SFRP1, SFRP2, SFRP4, and SFRP5 were analyzed from DNA and RNA obtained from these tissues.</p><p><strong>Results: </strong>A significant correlation was found between the methylation status and expression of the SFRP4 gene in the proximal colon in the patient group compared to controls (P = .018). For the methylation of the APC2 gene, 8 patients were methylated (40%), and 12 were unmethylated (60%), while 1 of the controls was methylated (6.7%) and 14 were unmethylated (93.3%) (P = .018). There was no statistically significant association between methylation, expression, and inflammation status for other genes between patients and controls.</p><p><strong>Conclusion: </strong>In ulcerative colitis, inflammation is thought to be associated with both increased APC2 methylation and decreased expression findings due to decreased SFRP4 methylation in non-inflamed areas. However, more research is needed to establish a link with ulcerative colitis-related neoplasia.</p>","PeriodicalId":51205,"journal":{"name":"Turkish Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutrophil-Lymphocyte Ratio and LDH/Albumin Ratio as Biomarkers for Severity and Mortality in Acute Pancreatitis.","authors":"Göksel Bengi, İbrahim Çelik, Süleyman Dolu, Soner Önem, Müjde Soytürk, Serkan Rendeci, Ömer Topalak, Hale Akpinar","doi":"10.5152/tjg.2025.24828","DOIUrl":"https://doi.org/10.5152/tjg.2025.24828","url":null,"abstract":"<p><strong>Background/aims: </strong>Acute pancreatitis (AP) is a common and potentially severe condition, and early identification of its severity is critical for appropriate clinical management. This study aimed to investigate the role of the Neutrophil-Lymphocyte Ratio (NLR) and Lactate dehydrogenase (LDH)/Albumin Ratio (LAR) in predicting the severity and prognosis of patients with AP and to determine the optimal NLR value.</p><p><strong>Materials and methods: </strong>The demographic, clinical, and laboratory data of patients diagnosed with AP were retrospectively analyzed. Neutrophil-Lymphocyte Ratio was measured at admission (0 hours), and at 24 and 48 hours; C-reactive protein (CRP) values were recorded at 0 and 48 hours; and the LAR was calculated based on LDH and albumin values measured at 48 hours post admission. These values were compared with disease severity, mortality, organ failure, length of hospital stay, and the need for intensive care according to Ranson and bedside index of severity in AP (BISAP) scores.</p><p><strong>Results: </strong>According to the BISAP scoring, 38 patients (16%) were classified as having severe AP, while 200 patients (84%) had mild AP. The best parameter for predicting severe AP was found to be the 24-hour NLR with a sensitivity of 79% and specificity of 67%. The best parameter for predicting mortality and organ failure was the NLR at 48 hours. There was a statistically significant difference between the length of hospital stay and the need for intensive care with the CRP value at 48 hours. Additionally, there was a statistically significant relationship between LAR and mortality, length of hospital stay, organ failure, and the need for intensive care.</p><p><strong>Conclusion: </strong>This study demonstrates that the NLR and the LDH/Albumin Ratio are important and easily accessible markers for determining the severity and prognosis of AP. The NLR at 48 hours is an effective parameter for predicting mortality and organ failure, while the LDH/Albumin Ratio is significant in predicting mortality.</p>","PeriodicalId":51205,"journal":{"name":"Turkish Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Pancreatic Enzyme Insufficiency in the Etiology of Functional Dyspepsia Resistant to Standard Treatment.","authors":"Fatih Kemik, Gozde Ceylan, Abdurrahman F Aydin, Bilger Çavuş, Asli Ormeci, Ziya Imanov, Ibrahim V Senkal, Kenan Nuriyev, Zulal Istemihan, Filiz Akyuz, Selman F Besisik, Sabahattin Kaymakoglu, Kadir Demir","doi":"10.5152/tjg.2025.24729","DOIUrl":"10.5152/tjg.2025.24729","url":null,"abstract":"<p><strong>Background/aims: </strong>Functional dyspepsia (FD) is diagnosed in the absence of an identifiable organic cause. Pancreatic enzyme insufficiency (PEI) remains an underrecognized condition in these patients. This study aimed to investigate the prevalence of PEI among FD patients unresponsive to standard therapy and to evaluate its clinical and biochemical characteristics.</p><p><strong>Materials and methods: </strong>A total of 154 patients diagnosed with FD were followed, among which 66 patients who did not respond to at least 4 weeks of standard treatment, including acid-reducing therapies, prokinetics, and antidepressants, were evaluated. Additionally, 34 healthy volunteers were included as a control group. Organic pathologies were excluded in all 66 patients with FD resistant to standard treatment using endoscopy, endoscopic biopsy, and imaging methods. Fecal elastase-1 (FE-1) enzyme levels were measured to determine the prevalence of PEI in both groups.</p><p><strong>Results: </strong>Pancreatic enzyme insufficiency was detected in 5 (7.57%) of the 66 treatment-resistant FD patients, while none of the controls had PEI. The prevalence of PEI was significantly higher in diabetic patients than in non-diabetic patients within the study group (P = .037). Patients with diarrhea, sticky stools, and frequent foul-smelling stools exhibited a higher prevalence of PEI (P = .022, P = .001, and P = .004, respectively). In the study group, PEI patients had lower serum calcium, phosphorus, and magnesium levels than the control group (P = .018, P = .011, and P = .001, respectively).</p><p><strong>Conclusion: </strong>Pancreatic enzyme insufficiency was identified in 7.57% of patients resistant to standard treatment. In patients resistant to standard therapy for at least 4 weeks, the presence of symptoms such as diarrhea, sticky stools, and foul-smelling stools, along with diabetes mellitus and low serum calcium, phosphorus, and magnesium levels, may warrant consideration of PEI as a potential underlying condition.</p>","PeriodicalId":51205,"journal":{"name":"Turkish Journal of Gastroenterology","volume":" ","pages":"467-473"},"PeriodicalIF":1.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of Inflammatory Markers in Septic Critically Ill Patients with Chronic Liver Disease: A Retrospective Analysis.","authors":"Nazlıhan Boyacı Dündar, Kamil İnci, Gülbin Aygencel, Melda Türkoğlu, Onur Gökçe, Mehmet Cindoruk","doi":"10.5152/tjg.2025.24794","DOIUrl":"https://doi.org/10.5152/tjg.2025.24794","url":null,"abstract":"<p><strong>Background/aims: </strong>Septic patients with chronic liver disease (CLD) experience high morbidity and mortality rates, particularly in the intensive care unit (ICU) setting, due to immune dysfunction. Despite their vulnerability, data on prognostic markers remain scarce, particularly when assessed in conjunction with disease severity scores. This study aimed to evaluate the prognostic value of various inflammatory markers, including white blood cell count (WBC), neutrophil-to-lymphocyte ratio (NLR), lactate, and lactate-to-albumin ratio (LAR), in septic critically ill CLD patients.</p><p><strong>Materials and methods: </strong>A retrospective cohort study was conducted on 126 septic CLD patients admitted to ICU. Data on demographics, clinical scores, inflammatory markers, and clinical outcomes were collected. Logistic regression and ROC analyses were used to identify independent predictors of ICU mortality.</p><p><strong>Results: </strong>Intensive care unit mortality was 66%. In addition to higher Acute Physiology and Chronic Health Evaluation II (APACHE II) (39.3 ± 7.2 vs. 21 ± 5.1, P < .001), Sequential Organ Failure Assessment (12.4 ± 3.5 vs. 8.5 ± 3.1, P < .001), CLIF-C ACLF [63 (54-69) vs. 50 (41- 53)] scores, ICU non-survivors had higher WBC (median: 14 400/µL vs. 7300/µL, P < .001), lactate (median: 4.6mmol/L vs. 2.4mmol/L, P < .001), NLR (median: 12.5 vs. 9, P = .015), and LAR (median: 2.15 vs. 0.93, P < .001) compared to survivors. Multivariate analysis identified APACHE II (OR 1.183, 95% CI: 1.003-1.396, P = .046), CLIF-C ACLF (OR 1.104, 95% CI: 1.002-1.216, P = .046), and LAR (OR 2.992, 95% CI: 1.277-7.009, P = .012) as independent predictors of ICU mortality. The LAR was the most significant inflammatory marker (area under the curve: 0.783, cut-off: 1.17), even in the subgroup of patients with low acute decompensation scores based on the CLIF-C ACLF score.</p><p><strong>Conclusion: </strong>The LAR was a valuable prognostic marker for ICU mortality in septic CLD patients, even in the absence of advanced organ failure. This marker potentially outperforms other traditional inflammatory markers and could aid in early risk stratification for critically ill septic CLD patients.</p>","PeriodicalId":51205,"journal":{"name":"Turkish Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-line Eradication of Helicobacter pylori Infection with High-Dose Amoxicillin and Vonoprazan: A Systematic Review and Meta-analysis.","authors":"Hongxiu Yu, Zhengwen Zhou, Zhi Liu","doi":"10.5152/tjg.2025.24371","DOIUrl":"10.5152/tjg.2025.24371","url":null,"abstract":"<p><strong>Background/aims: </strong>Due to increasing Helicobacter pylori resistance, the effectiveness of proton pump inhibitor-based regimens has diminished. There is a need to assess the high-dose amoxicillin (≥3 g/day) and vonoprazan dual therapy through meta-analysis to determine if it is more effective than previous protocols.</p><p><strong>Materials and methods: </strong>A computer search of PubMed, Web of Science, Cochrane Library, Embase, and ClinicalTrials.gov was carried out to identify randomized controlled trials of massive dose amoxicillin and vonoprazan double treatment for H. pylori infection, up to June 2023. The primary outcome measures were the eradication rate and adverse event rate.</p><p><strong>Results: </strong>A total of 7 studies encompassing 2601 patients were analyzed. The eradication rate of the high-dose dual group has no statistically significant differences compared to the control group (non-high-dose amoxicillin combined with vonoprazan) in intention-totreat (ITT) [OR=1.12, 95% CI (0.85, 1.48), P = .42] and per-protocol (PP) analysis [OR=1.08, 95% CI (0.74, 1.58), P = .69]. The incidence of adverse events [OR=0.63, 95% CI (0.45, 0.88), P = .007] was significantly reduced in the dual treatment group. Subgroup analysis revealed that the eradication rate in China [OR=1.34, 95% CI (1.01, 1.87), P = .04] was higher for the high-dose dual group compared with the control group in ITT analysis.</p><p><strong>Conclusion: </strong>The eradication rate of high-dose amoxicillin and vonoprazan dual regimen is similar to that of previous regimens, and the adverse event rate is significantly lower.</p>","PeriodicalId":51205,"journal":{"name":"Turkish Journal of Gastroenterology","volume":" ","pages":"410-419"},"PeriodicalIF":1.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Etrasimod in Treatment of Ulcerative Colitis: A Comprehensive Review.","authors":"Osman Cagin Buldukoglu, Yusuf Erzin, Ayhan Hilmi Cekin, Silvio Danese","doi":"10.5152/tjg.2025.25148","DOIUrl":"10.5152/tjg.2025.25148","url":null,"abstract":"<p><p>Ulcerative colitis (UC) is a chronic, inflammatory disease of the colon. The unpredictable, systemic, and debilitating nature of UC puts disease management and patient monitoring at a pivotal point. Despite substantial development in pharmacotherapies for UC in recent years, a significant proportion of patients either fail to respond to treatment or lose their response over the course of the disease. The backbone of disease management in UC is 5-aminosalicylic acid (5-ASA), but patients unresponsive to 5-ASA or with severe disease require advanced therapies including tumor necrosis factor-alpha inhibitors (TNFi), anti-integrins, anti-interleukins and small molecule therapy, Janus kinase (JAK) inhibitors, and S1PR modulators. This review will briefly overview the current state of medical therapeutic options in UC, with further detailing the molecular and clinical aspects of Etrasimod, a sphingosine-1-phosphate receptor (S1PR) modulator.</p>","PeriodicalId":51205,"journal":{"name":"Turkish Journal of Gastroenterology","volume":"36 6","pages":"336-342"},"PeriodicalIF":1.4,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Scoring in Biliary Atresia.","authors":"Şükrü Güngör, Fatma İlknur Varol, Ebubekir Altundaş, Emre Gök, Turan Yıldız, Sevgi Demiröz","doi":"10.5152/tjg.2025.24469","DOIUrl":"10.5152/tjg.2025.24469","url":null,"abstract":"<p><p>Background/Aims: The aim of this study was to develop a diagnostic scoring model to predict the need for intraoperative cholangiography in patients with neonatal cholestasis suspected of having biliary atresia (BA) and to aid in the early diagnosis of BA. Materials and Methods: Data from 70 patients with neonatal cholestasis who underwent intraoperative cholangiography with a preliminary diagnosis of BA between 2019 and 2024 were retrospectively reviewed. Data from patients with and without BA were compared. Thescoring was based on 3 parameters: acholic stool observed clinically on inspection, findings suggestive of BA on ultrasound, and elevated gamma-glutamyl transferase (GGT) levels. The best GGT cut-off point for the diagnosis of BA was determined by receiver operating characteristic analysis. The diagnostic success of the scoring model for BA was statistically evaluated. Results: There were no significant differences in age and gender between BA and non-BA groups. Gamma-glutamyl transferase levels were elevated in all patients. Acholic stools were present in 98% of BA patients. Ultrasound findings suggestive of BA were present in 88.5% of patients with BA. The authors found the best GGT cut-off value for the diagnosis of BA to be ≥366 (73% sensitivity, 77.8% specificity). In the scoring model the authors developed, the presence of 2 parameters provided diagnostic success with high sensitivity (98%) and specificity (83.3%). Conclusion: The study provides a reliable and sensitive diagnostic criterion to determine the need for intraoperative cholangiography in infants with neonatal cholestasis. These data should be validated in larger prospective case series.</p>","PeriodicalId":51205,"journal":{"name":"Turkish Journal of Gastroenterology","volume":"1 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"hsa_circ_0007376 Promotes Gastric Cancer Proliferation and Malignant Metastasis by Enhancing the Stability of IGF2BP3.","authors":"LinHu Liang, Ting Han, ZhengRong Zhang, ZhengWu Cheng, HaoRan Li","doi":"10.5152/tjg.2025.24491","DOIUrl":"10.5152/tjg.2025.24491","url":null,"abstract":"<p><p>Background/Aims: This study investigated the action of hsa_circ_0007376 in promoting the proliferation and metastasis of gastric cancer (GC). Materials and Methods: hsa_circ_0007376 was detected in GC tissues and cells by quantitative reverse transcription polymerase chain reaction. RNase R digestion, nucleoplasmic separation, and actinomycin D assays were conducted to detect the presence of hsa_circ_0007376 and its cyclic nature. The tumor-promoting effect of hsa_circ_0007376 in GC cells was verified by CCK-8, colony formation, wound healing, and Transwell assays. An interplay between hsa_circ_0007376 and insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) was confirmed by FISH, RIP, and RNA pull-down experiments. The function of hsa_circ_0007376 on GC proliferation and metastasis was evaluated in vivo in a GC xenograft mouse model. Results: hsa_circ_0007376 was highly expressed in GC. hsa_circ_0007376 was associated with lymphatic metastasis, Tumor node metastasis (TNM) stage, and tumor size in GC. When hsa_circ_0007376 was knocked down, GC cells were prevented from proliferating, migrating, and invading, as well as being prevented from metastasizing. hsa_circ_0007376 was able to bind to IGF2BP3, thereby promoting GC. Conclusion: hsa_circ_0007376 may play a role in GC by interacting and enhancing the stability of the IGF2BP3 protein.</p>","PeriodicalId":51205,"journal":{"name":"Turkish Journal of Gastroenterology","volume":"1 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"lncRNA FENDRR Predicts Adverse Prognosis and Regulates the Development of Esophageal Squamous Cell Carcinoma Through Negatively Modulating miR-495-3p.","authors":"Yangyang Xue, Ran Yang, Ping Gong, Hongjuan Zhu","doi":"10.5152/tjg.2025.24350","DOIUrl":"https://doi.org/10.5152/tjg.2025.24350","url":null,"abstract":"<p><p>Background/Aims: Esophageal squamous cell carcinoma (ESCC) is a major subtype of esophageal carcinoma and is highly prevalent in China. Identification of effective biomarkers could benefit ESCC management and therefore improve clinical outcomes. Evaluating the expression and significance of long non-coding RNA Fetal-lethal non-coding developmental regulatory RNA (FENDRR) in ESCC aims to provide a biomarker candidate for ESCC. Materials and Methods: This study enrolled 117 ESCC patients and collected tissue samples. The expression of FENDRR in collected samples was analyzed by polymerase chain reaction. The Chi-square, Kaplan-Meier, and Cox analyses were performed to reveal its clinical value. In ESCC cells, FENDRR was regulated by cell transfection, and its effect on cell growth and motility was evaluated. Results: FENDRR was downregulated in ESCC and was associated with large tumor size, poor differentiation, late TNM stage, positive lymph node metastasis, and adverse development-free survival of ESCC patients. FENDRR acted as an adverse indicator for the prognosis of ESCC patients. miR-495-3p was negatively regulated by FENDRR. Overexpressing FENDRR significantly suppressed ESCC cell growth and metastasis, while miR-495-3p reversed these effects. Conclusion: Downregulated FENDRR in ESCC predicted the malignant development and adverse prognosis of ESCC patients. FENDRR served as a tumor suppressor of ESCC by modulating miR-495-3p.</p>","PeriodicalId":51205,"journal":{"name":"Turkish Journal of Gastroenterology","volume":"1 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144152595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gasdermin D: A New Inflammatory Biomarker in Assessing Clinical Disease Activity in Crohn's Disease.","authors":"Osman Cagin Buldukoglu, Serkan Ocal, Galip Egemen Atar, Besir Kaya, Muhammet Devran Isik, Gul Aydin Tigli, Serdar Akca, Ferda Akbay Harmandar, Yesim Cekin, Ayhan Hilmi Cekin","doi":"10.5152/tjg.2025.24726","DOIUrl":"10.5152/tjg.2025.24726","url":null,"abstract":"<p><p>Background/Aims: Crohn's disease (CD) is an inflammatory, progressive disorder requiring monitoring of treatment response and disease course. Gasdermin D (GSDMD), a protein belonging to the gasdermin protein family, plays a role in inflammatory cell death, and activation of GSDMD has been shown to be a component of the pathogenesis of inflammatory bowel disease. Considering the role that GSDMD plays in inflammation, it was hypothesized that disease activity in CD may be correlated with serum GSDMD levels. The aim of this study was to assess the strength of GSDMD in predicting clinical disease activity in patients with CD in a prompt and easy manner. Materials and Methods: This cross-sectional study was conducted over a span of 22 months from September 2022 to June 2024. A total of 61 patients with CD were included in the study. Demographic data, disease- and treatment-related data, and laboratory workups of the patients were recorded and analyzed. Results: Gasdermin D levels were statistically significant in their correlation with the Harvey-Bradshaw Index (HBI) scores of the study population (P = .019). A threshold value of 5 ng/mL for GSDMD had a sensitivity of 84.6% and a specificity of 91.7% in differentiating patients with remission or mild disease from those with moderate or severe disease, according to HBI. Conclusion: This pioneering study revealed that serum GSDMD can be used as a biomarker to assess clinical disease activity in patients with CD. Future studies incorporating colonoscopic evaluation into the equation will provide more insight into the use of this protein as a surrogate marker of disease progression in CD.</p>","PeriodicalId":51205,"journal":{"name":"Turkish Journal of Gastroenterology","volume":"1 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}